Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Orchard Therapeutics Plc ADR (ORTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,597,966
  • Shares Outstanding, K 85,866
  • Annual Sales, $ 2,080 K
  • Annual Income, $ -230,500 K
  • 60-Month Beta N/A
  • Price/Sales 766.01
  • Price/Cash Flow N/A
  • Price/Book 5.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.41
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.21 +14.81%
on 04/25/19
20.50 -9.22%
on 05/06/19
+1.56 (+9.15%)
since 04/24/19
3-Month
14.33 +29.87%
on 03/11/19
21.64 -14.00%
on 04/11/19
+2.83 (+17.93%)
since 02/22/19

Most Recent Stories

More News
Orchard Therapeutics to Webcast Conference Call of First Quarter 2019 Financial Results on May 28, 2019

Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Announces Clinical Proof-of-Concept Data for Gene Therapy OTL-300 Demonstrating Efficacy in Transfusion-Dependent Beta-Thalassemia

Study Used the GLOBE Lentiviral Vector and Treated Adult and Pediatric Patients with Severe Phenotypes

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)
Will Orchard Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Orchard Therapeutics.

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD

Compared to Natural History, Late Infantile Patients Demonstrated Gross Motor Function Scores Higher by 65 and 72 Percentage Points at 2- and 3-Years Post Gene Therapy; Early Juvenile Patients Demonstrated...

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights

Three Lead Programs for MLD, ADA-SCID and WAS on Track for Regulatory Filings Over the Next Three Years, with MLD and ADA-SCID Expected in 2020

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)
Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative...

ORTX : 18.61 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ORTX with:

Business Summary

Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based...

See More

Key Turning Points

2nd Resistance Point 20.07
1st Resistance Point 19.34
Last Price 18.61
1st Support Level 17.44
2nd Support Level 16.27

See More

52-Week High 21.64
Last Price 18.61
Fibonacci 61.8% 16.68
Fibonacci 50% 15.14
Fibonacci 38.2% 13.61
52-Week Low 8.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar